Perspective Therapeutics (CATX) Tax Rate (2022 - 2023)
Perspective Therapeutics' (CATX) quarterly Tax Rate came in at 7.14% in Q4 2023, down 2164.0% year-over-year from 0.35% in Q4 2022, and down 107.4% quarter-over-quarter from 96.59% in Q1 2023.
Powered by 
Analysis
Perspective Therapeutics (CATX) Tax Rate (2022 - 2023) Analysis & Trends
Perspective Therapeutics has disclosed Tax Rate across 2 years of filings, most recently posting 7.14% for Q4 2023.
- In Q4 2023, Tax Rate fell 2164.0% year-over-year to 7.14%; the TTM figure through Dec 2023 stood at 18.91% (up 1349.0% YoY), while the FY2023 annual figure was 18.91%, changed N/A from the prior year.
- Tax Rate came in at 7.14% for Q4 2023 at Perspective Therapeutics, down from 96.59% in the prior quarter.
- In the past five years, Tax Rate ranged from a high of 96.59% in Q1 2023 to a low of 7.14% in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Tax Rate (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 14.20% |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -2.36% |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 20.98% |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 15.11% |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | -10.89% |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -1.96% |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 7.49% |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 26.36% |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 1.34% |
| 10 | Perspective Therapeutics | 361.95 Mn | 361.95 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | -7.14% |
| Mar 31, 2023 | 96.59% |
| Dec 31, 2022 | 14.49% |